These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 498294)

  • 61. [The role of DL and DH degradation products in the reactions of the plasmin hydrolysis of fibrinogen and fibrin].
    Rozenfel'd MA; Leonova VB; Khavkina LS
    Izv Akad Nauk SSSR Biol; 1991; (3):334-42. PubMed ID: 1835465
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Fibrin/fibrinogen degradation products in amniotic fluid.
    Purdie DW; Howie PW; Edgar W; Prentice CR
    Br J Obstet Gynaecol; 1975 Oct; 82(10):845-6. PubMed ID: 1103962
    [No Abstract]   [Full Text] [Related]  

  • 63. [C3 component, fibrinogen and fibrin degradation products as well as plasminogen in amniotic fluid].
    Cisło M
    Pol Tyg Lek; 1978 Jan; 33(4):155-7. PubMed ID: 652636
    [No Abstract]   [Full Text] [Related]  

  • 64. Diagnostic efficacy of estimating fibrinogen/fibrin degradation products in pleural and peritoneal effusion fluids.
    Dube B; Narayanan R; Dube RK; Singh VP
    J Assoc Physicians India; 1984 Jun; 32(6):493-5. PubMed ID: 6511725
    [No Abstract]   [Full Text] [Related]  

  • 65. [The clinical manifestations and the plasma levels of fibronectin and fibrin-fibrinogen degradation products in different morphological forms of chronic hepatitis].
    Malaia LT; Iabluchanskiĭ NI; Panchuk SN; Babak OIa
    Ter Arkh; 1991; 63(11):44-6. PubMed ID: 1810062
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Microquantitative estimation of C-reactive protein (CRP) in sera from patients with tumors of female genital organs (author's transl)].
    Takizawa K; Kawana T; Shiromizu K; Sakamoto S
    Nihon Gan Chiryo Gakkai Shi; 1978 Dec; 13(6):712-20. PubMed ID: 744888
    [No Abstract]   [Full Text] [Related]  

  • 67. Evaluation and comparison of hemocoagulation parameters both in serum and in ascites from patients with gynecologic malignancies.
    Varcaccio-Garofalo G; Selvaggi L; Capozza G; Orlando E; Ferreri R; Restaino A
    Eur J Gynaecol Oncol; 1982; 3(2):113-4. PubMed ID: 7166171
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Determination of fibrinogen and fibrin degradation products].
    Fujimaki M; Ikematsu S
    Nihon Rinsho; 1976; 34 suppl():2390-7. PubMed ID: 1033361
    [No Abstract]   [Full Text] [Related]  

  • 69. [Quantitative analysis of fibrinmonomer in Arwin-therapy (author's transl)].
    Rath NF; Wuppermann T
    Blut; 1978 Jan; 36(1):9-14. PubMed ID: 623920
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Fibrin/fibrinogen degradation products in pleural exudate.
    Astedt B; Adielsson G; Mattsson W
    Lancet; 1976 Aug; 2(7982):414. PubMed ID: 73867
    [No Abstract]   [Full Text] [Related]  

  • 71. [Clinical experience with butocin in the treatment of malignant tumours of the female genitalia (author's transl)].
    Dvorák O; Slavík V
    Sb Lek; 1976 Aug; 78(8):241-4. PubMed ID: 981950
    [No Abstract]   [Full Text] [Related]  

  • 72. [Use of computer tomography in the gynecological tumour diagnosis - problems and demonstration of diagnostical possibilities (author's transl)].
    Pötzschke B; Räber G; Lüning M
    Radiol Diagn (Berl); 1982; 23(2):190-7. PubMed ID: 7100440
    [No Abstract]   [Full Text] [Related]  

  • 73. [Information concent of arteriographic examinations in primary gynaecological tumours (author's transl)].
    Platzbecker H; Köhler K
    Radiol Diagn (Berl); 1974; 15(2):121-31. PubMed ID: 4848953
    [No Abstract]   [Full Text] [Related]  

  • 74. [The "healing" of carcinomas (author's transl)].
    Hauser GA
    Ther Umsch; 1979 Jun; 36(6):482-3. PubMed ID: 462398
    [No Abstract]   [Full Text] [Related]  

  • 75. [Epidemiologic survey of malignant tumors of the genitalia in Slovakia from 1954 (author's transl)].
    Zajacová E; Blasková O; Boháciková A; Manajlová O
    Bratisl Lek Listy; 1979 Sep; 72(3):289-99. PubMed ID: 509276
    [No Abstract]   [Full Text] [Related]  

  • 76. [Estimation of the degradation products of fibrinogen and fibrin (DPF) in malignant gynecological tumours (author's transl)].
    Kudela M; Fisherová E; Krc I
    Cesk Gynekol; 1979 Jul; 44(6):413-6. PubMed ID: 498294
    [No Abstract]   [Full Text] [Related]  

  • 77. [Fibrin and fibrinogen degradation products in head- and neck-tumors (author's transl)].
    Wilmes EH; Hochstrasser K
    Laryngol Rhinol Otol (Stuttg); 1978 Dec; 57(12):1083-6. PubMed ID: 732487
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Fibrinogen degradation products in gynecologic neoplasms].
    Tatra G; Breitenecker G; Karsai I
    Fortschr Med; 1976 May; 94(13):752-4. PubMed ID: 955534
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Distinction between fibrinogen and fibrin degradation products in serum from patients with DIC (author's transl)].
    Yoshioka K; Yamamoto T; Yamauchi E; Mizuno S; Miyata H
    Rinsho Ketsueki; 1981 Sep; 22(9):1401-5. PubMed ID: 7334618
    [No Abstract]   [Full Text] [Related]  

  • 80. [Critical evaluation of new methods for studying fibrin degradation products].
    Prisco D
    Recenti Prog Med; 1989 May; 80(5):263-7. PubMed ID: 2669062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.